Women more likely to need walking aids but less likely to use them – studyApple’s investment in the UK over the last five years has now surpassed £18 billion, with the technology giant’s engineering teams in the country doubling in that time, the iPhone maker has said. The US tech giant said it now supported 550,000 jobs in the UK through direct employment, its supply chain and the economy around its App Store – with app developers having earned nearly £9 billion since it launched in 2008. Apple said its engineering teams were carrying out critical work on the firm’s biggest services, including key technology within Apple Intelligence, the iPhone maker’s suite of generative AI-powered tools which are expected to launch in the UK for the first time this week. Elsewhere, the firm said its growing TV empire, spearheaded by its Apple TV+ streaming service and production arm, had also helped boost its investment in the UK with Apple TV+ production in this country tripling in the last two years, the company said. Chief executive Tim Cook said: “We’ve been serving customers in the UK for more than 40 years, and we’re proud of our deep connection with communities across this country. “We’re thrilled to be growing our Apple teams here, and to keep supporting the extraordinary innovators, creators, and entrepreneurs who are pushing the boundaries of technology in so many ways.” The Chancellor Rachel Reeves said companies such as Apple were “intrinsic” to the UK’s prosperity by boosting jobs. “This government is laser focused on creating the right conditions for growth to help put more money in people’s pockets. “That’s what underpins the Plan for Change and is what has driven £63 billion worth of inward investment in the UK through our first international investment summit. “Companies like Apple are intrinsic to the success of our nation’s prosperity – helping deliver jobs, innovative technology, and boost infrastructure.”‘Saying congrats doesn’t hurt’: Touching F1 embrace caught on camera as stars bury hatchet - Fox Sports
NEW YORK, Dec. 12, 2024 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Hasbro, Inc. (NASDAQ: HAS) between February 7, 2022 and October 25, 2023, both dates inclusive (the “Class Period”), of the important January 13, 2025 lead plaintiff deadline. SO WHAT: If you purchased Hasbro common stock during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. WHAT TO DO NEXT: To join the Hasbro class action, go to https://rosenlegal.com/submit-form/?case_id=31157 or call Phillip Kim, Esq. at 866-767-3653 or email case@rosenlegal.com for more information. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than January 13, 2025. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm achieved the largest ever securities class action settlement against a Chinese Company at the time. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs’ Bar. Many of the firm’s attorneys have been recognized by Lawdragon and Super Lawyers. DETAILS OF THE CASE: According to the lawsuit, during the Class Period, defendants made false and/or misleading statements that represented the quality of inventory and the appropriateness of the levels of inventories carried by Hasbro and its retailers compared to customer demand. In truth, however, Hasbro had a significant buildup of inventory that it was struggling to manage and which far exceeded customer demand. As a result, defendants’ statements about Hasbro’s inventory, and what inventory levels reflected regarding demand, were materially false and misleading and/or lacked a reasonable basis. When the true details entered the market, the lawsuit claims that investors suffered damages. To join the Hasbro class action, go to https://rosenlegal.com/submit-form/?case_id=31157 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email case@rosenlegal.com for information on the class action. No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor’s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff. Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm , on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/ . Attorney Advertising. Prior results do not guarantee a similar outcome. ------------------------------- Contact Information: Laurence Rosen, Esq. Phillip Kim, Esq. The Rosen Law Firm, P.A. 275 Madison Avenue, 40th Floor New York, NY 10016 Tel: (212) 686-1060 Toll Free: (866) 767-3653 Fax: (212) 202-3827 case@rosenlegal.com www.rosenlegal.comLuigi Nicholas Mangione, the suspect in the fatal shooting of a healthcare executive in New York City, apparently was living a charmed life: the grandson of a wealthy real estate developer, valedictorian of his elite Baltimore prep school and with degrees from one of the nation's top private universities. Friends at an exclusive co-living space at the edge of touristy Waikiki in Hawaii where the 26-year-old Mangione once lived widely considered him a “great guy,” and pictures on his social media accounts show a fit, smiling, handsome young man on beaches and at parties. Now, investigators in New York and Pennsylvania are working to piece together why Mangione may have diverged from this path to make the violent and radical decision to gun down UnitedHealthcare CEO Brian Thompson in a brazen attack on a Manhattan street. The killing sparked widespread discussions about corporate greed, unfairness in the medical insurance industry and even inspired folk-hero sentiment toward his killer. But Pennsylvania Gov. Josh Shapiro sharply refuted that perception after Mangione's arrest on Monday when a customer at a McDonald's restaurant in Pennsylvania spotted Mangione eating and noticed he resembled the shooting suspect in security-camera photos released by New York police. “In some dark corners, this killer is being hailed as a hero. Hear me on this, he is no hero,” Shapiro said. “The real hero in this story is the person who called 911 at McDonald’s this morning.” Mangione comes from a prominent Maryland family. His grandfather, Nick Mangione, who died in 2008, was a successful real estate developer. One of his best-known projects was Turf Valley Resort, a sprawling luxury retreat and conference center outside Baltimore that he purchased in 1978. The Mangione family also purchased Hayfields Country Club north of Baltimore in 1986. On Monday, Baltimore County police officers blocked off an entrance to the property, which public records link to Luigi Mangione’s parents. Reporters and photographers gathered outside the entrance. The father of 10 children, Nick Mangione prepared his five sons — including Luigi Mangione’s father, Louis Mangione — to help manage the family business, according to a 2003 Washington Post report. Nick Mangione had 37 grandchildren, including Luigi, according to the grandfather's obituary. Luigi Mangione’s grandparents donated to charities through the Mangione Family Foundation, according to a statement from Loyola University commemorating Nick Mangione’s wife’s death in 2023. They donated to various causes, including Catholic organizations, colleges and the arts. One of Luigi Mangione’s cousins is Republican Maryland state legislator Nino Mangione, a spokesman for the lawmaker’s office confirmed. “Our family is shocked and devastated by Luigi’s arrest,” Mangione’s family said in a statement posted on social media by Nino Mangione. “We offer our prayers to the family of Brian Thompson and we ask people to pray for all involved.” Mangione, who was valedictorian of his elite Maryland prep school, earned undergraduate and graduate degrees in computer science in 2020 from the University of Pennsylvania, a university spokesman told The Associated Press. He learned to code in high school and helped start a club at Penn for people interested in gaming and game design, according to a 2018 story in Penn Today, a campus publication. His social media posts suggest he belonged to the fraternity Phi Kappa Psi. They also show him taking part in a 2019 program at Stanford University, and in photos with family and friends at the Jersey Shore and in Hawaii, San Diego, Puerto Rico, and other destinations. The Gilman School, from which Mangione graduated in 2016, is one of Baltimore’s elite prep schools. The children of some of the city’s wealthiest and most prominent residents, including Orioles legend Cal Ripken Jr., have attended the school. Its alumni include sportswriter Frank Deford and former Arizona Gov. Fife Symington. In his valedictory speech, Luigi Mangione described his classmates’ “incredible courage to explore the unknown and try new things.” Mangione took a software programming internship after high school at Maryland-based video game studio Firaxis, where he fixed bugs on the hit strategy game Civilization 6, according to a LinkedIn profile. Firaxis' parent company, Take-Two Interactive, said it would not comment on former employees. He more recently worked at the car-buying website TrueCar, but has not worked there since 2023, the head of the Santa Monica, California-based company confirmed to the AP. From January to June 2022, Mangione lived at Surfbreak, a “co-living” space at the edge of touristy Waikiki in Honolulu. Like other residents of the shared penthouse catering to remote workers, Mangione underwent a background check, said Josiah Ryan, a spokesperson for owner and founder R.J. Martin. “Luigi was just widely considered to be a great guy. There were no complaints,” Ryan said. “There was no sign that might point to these alleged crimes they’re saying he committed.” At Surfbreak, Martin learned Mangione had severe back pain from childhood that interfered with many aspects of his life, including surfing, Ryan said. “He went surfing with R.J. once but it didn’t work out because of his back,” Ryan said, but noted that Mangione and Martin often went together to a rock-climbing gym. Mangione left Surfbreak to get surgery on the mainland, Ryan said, then later returned to Honolulu and rented an apartment. An image posted to a social media account linked to Mangione showed what appeared to be an X-ray of a metal rod and multiple screws inserted into someone's lower spine. Martin stopped hearing from Mangione six months to a year ago. An X account linked to Mangione includes recent posts about the negative impact of smartphones on children; healthy eating and exercise habits; psychological theories; and a quote from Indian philosopher Jiddu Krishnamurti about the dangers of becoming “well-adjusted to a profoundly sick society.” Mangione likely was motivated by his anger at what he called “parasitic” health insurance companies and a disdain for corporate greed, according to a law enforcement bulletin obtained by AP. He wrote that the U.S. has the most expensive healthcare system in the world and that the profits of major corporations continue to rise while “our life expectancy” does not, according to the bulletin, based on a review of the suspect’s handwritten notes and social media posts. He appeared to view the targeted killing of the UnitedHealthcare CEO as a symbolic takedown, asserting in his note that he is the “first to face it with such brutal honesty,” the bulletin said. Mangione called “Unabomber” Ted Kaczynski a “political revolutionary” and may have found inspiration from the man who carried out a series of bombings while railing against modern society and technology, the document said. Associated Press reporters Lea Skene in Baltimore; Jennifer Sinco Kelleher in Honolulu; Maryclaire Dale in Philadelphia; John Seewer in Toledo, Ohio; and Michael Kunzelman in Washington, D.C., contributed to this report.Zegras had surgery Thursday, the team announced. Zegras was injured last week on a fairly innocent-looking play during the Ducks' 4-1 loss to Vegas in Anaheim. Zegras and William Karlsson only briefly got their skates and stick blades entangled, but Zegras needed help to get off the ice after taking a fall. Zegras' torn meniscus is his third major injury in just over a year, although a torn meniscus is likely a fortunate outcome for a knee injury that could have been much worse. He was limited to 31 games last season by two injury setbacks, including a broken ankle that required surgery. Zegras has four goals and six assists in 24 games this season for Anaheim, which had lost four straight heading into its road game against Toronto on Thursday night. The Ducks surprisingly activated forward Robby Fabbri from injured reserve before they faced the Maple Leafs. Fabbri had arthroscopic knee surgery on Nov. 15 and is progressing much faster than his initial predicted timeline of six to eight weeks. AP NHL: https://apnews.com/NHL
TORONTO — Bruce Brown intercepted a pass and streaked down the court, driving past some token defence from Atlanta Hawks forward Jalen Johnson for a one-handed slam dunk. Brown’s Toronto Raptors teammates burst off the home team’s bench, cheering for the veteran forward. “It’s just because they didn’t think I can jump, because I haven’t jumped really, or they haven’t seen it, and then they didn’t see it the last year,” Brown said, adding he knew he would dunk as soon as he crossed half-court. “I told them I could do it and I was like, ‘if I get the chance to, I’mma dunk it.'” It was Brown’s first dunk in eight months as he scored 12 points and had three rebounds off the bench in his season debut on Sunday as Toronto lost to Atlanta 136-107. He’d missed the first 31 games of the Raptors season as he recovered from arthroscopic knee surgery on Sept. 20, a process that took longer than he expected. “I thought I was gonna be out like six to eight weeks but some things didn’t go my way,” said Brown. “There was a lot of swelling in there for a while. “Things happened, and then I was supposed to come back, like, three, four weeks ago, but there was still swelling there, so they told me to take my time.” Brown averaged 9.6 points, 3.8 rebounds, 2.7 assists, 0.7 steals and 0.3 blocks over 34 games with the Raptors last season. He was traded from the Indiana Pacers to Toronto on Jan. 18 as part of a package for all-star forward Pascal Siakam. He’s averaged 8.9 points, 4.2 rebounds and 2.5 assists over his career in 416 games with the Detroit Pistons, Brooklyn Nets, Denver Nuggets, Indiana and Toronto. Brown’s return doesn’t just add depth to the Raptors’ lineup, but brings some much-needed energy to a struggling team that has lost 10 in a row. “You see him get out there and put his body on the line after being out for so long,” said Scottie Barnes, who led Toronto with 19 points, eight rebounds, and five assists but eight turnovers in the loss. “He’s making himself so tired out there just guarding, pushing himself. That’s what the team needs. “We’ve all got to match that energy every single night. That’s the effort we’re going to need in order to win games.” Head coach Darko Rajakovic said that fatigue is a major factor in the NBA’s longest active losing skid. He said that a lack of focus played a role in Toronto’s season-high 31 turnovers on Sunday. “We hit a wall. We look tired. We look drained,” said Rajakovic. “Guys are not in a rhythm. That’s the reality that we’re in right now. We’ve got to find a way to get out of it.” It was the third consecutive game where the Raptors had given up over 130 points, and second 29-point blowout in a row. “Getting beat by 30, man, at home — that’s unacceptable,” said Barnes. “We can’t be doing that. We got to go out there and play harder, be smarter. “We had a lot of turnovers today. We can’t allow this to happen.” Brown was more optimistic. “We just need some rest, and we’ll push through it,” he said, noting that a stomach flu had spread through Toronto’s locker room. “I mean, all teams have this at some point, even championship teams, so we’ll push through it. We’ll be fine.” This report by The Canadian Press was first published Dec. 29, 2024. John Chidley-Hill, The Canadian Press
HOUSTON (AP) — Will Levis threw for 278 yards and his 70-yard touchdown pass to Chig Okonkwo put Tennessee on top in the fourth quarter and the Titans held on for a 32-27 win over the Houston Texans on Sunday. Okonkwo grabbed a short pass and rumbled for the touchdown to put the Titans (3-8) up 30-27 with 91⁄2 minutes remaining. Safety Eric Murray missed a tackle that would have stopped him near midfield. The Texans (7-5) had a chance to tie it with less than two minutes remaining, but Ka’imi Fairbairn’s 28-yard field-goal attempt sailed wide left. He fell to the ground after the miss before getting up and slamming his helmet on the field. Titans coach Brian Callahan held both hands in the air and smiled after watching the miss that allowed his team to win on a day it had three turnovers. The Texans forced a three-and-out, but couldn’t move the ball after that and Harold Landry sacked C.J. Stroud in the end zone for a safety to make it 32-27 and allow Tennessee to snap a two-game skid. Stroud threw for 247 yards and two touchdowns, but also threw two interceptions as the AFC South-leading Texans lost for the third time in four games. Jimmie Ward had a 65-yard interception return for a touchdown in the third quarter and the Texans tied a franchise record with eight sacks. But the offense sputtered for most of the game as Joe Mixon was held to 22 yards on 14 carries. Tennessee extended the lead to 23-17 on a 51-yard field goal by Nick Folk with nine minutes left in the third. Stroud threw his second interception with about 90 seconds left in the third quarter but Ward’s touchdown came three plays later to put the Texans on top 24-23. The Titans fumbled a punt early in the fourth quarter and Houston recovered it. A 54-yard field goal by Fairbairn extended the lead to 27-23 with about 10 minutes to go. Dameon Pierce returned the opening kickoff 80 yards to get the Texans in the red zone. Houston cashed in on the next play when Stroud found rookie Cade Stover on a 19-yard pass for his first touchdown reception. The Titans trailed by four after a field goal by Folk when Nick Westbrook-Ikhine got in front of the defense and was wide open for a 38-yard TD catch that made it 10-7 late in the first quarter. Tennessee extended the lead to 17-7 when Tony Pollard ran 10 yards for a touchdown with about 11 minutes left in the second. Pollard finished with 119 yards and a touchdown. Nico Collins scored on a 5-yard reception with about six minutes left in the second. Levis fumbled on the Houston 32 with 31⁄2 minutes left in the first half and Houston recovered the ball. Stroud connected with Collins on a 56-yard pass on the next play, but the Texans couldn’t move the ball and settled for a 28-yard field goal to tie it at 17-17. Houston forced a punt after that, but rookie Jarvis Brownlee Jr. got his first career interception two plays later to give Tennessee the ball back. Folk’s 56-yard field goal, which tied his career long, put the Titans up 20-17 at halftime. The Titans were without cornerback L’Jarius Sneed, after he was placed on injured reserve with a quadriceps injury, and safety Amani Hooker, who was added to the injury report Sunday morning with an illness. Hooker leads the Titans with three interceptions. ... Houston S Jalen Pitre injured his shoulder in the second quarter and didn’t return. ... CB Ka’dar Hollman left in the fourth quarter with a knee injury. Titans: Visit the Commanders next Sunday. Texans: Visit Jacksonville next Sunday. AP NFL: https://apnews.com/hub/nfl Copyright 2024 The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed without permission.
Alpha Cognition Announces Voluntary Delisting from CSEI’m A Celebrity’s Coleen Rooney reveals her surprising budget family holidays to Butlins despite living in £20m mansion
Brazilian President Luiz Inacio Lula da Silva underwent surgery to remove a drain from his skull, a procedure carried out to relieve bleeding. According to his doctors, he remains "lucid and speaking normally." The 79-year-old leader is expected to be discharged from the hospital early next week. Despite his health challenges, a senior aide confirmed Lula's intention to run for re-election in 2026 as the ruling Workers Party candidate. This announcement comes amid public scrutiny of his age and health as potential barriers to a fourth term. Polls show divided opinion on Lula's candidacy, with a slight increase in those supporting his run. If an election scenario pits him against conservative rivals, it is suggested he would emerge victorious. The political left fears a lack of leadership succession if Lula steps down. (With inputs from agencies.)
And single people are more likely to use mobility tools compared to those who are married, according to researchers from University College London (UCL) and the London School of Hygiene and Tropical Medicine (LSHTM). Researchers looked at information from a group of more than 12,000 adults in England aged 50 to 89 who were tracked over a 13-year period. At the start of the study, 8,225 adults had no mobility difficulty and did not use mobility assistive products (MAPs). Some 2,480 were deemed to have “unmet need” and 1,375 were using mobility aids. During the follow-up period, there were 2,313 “transitions” where people went from having no mobility issues to needing some help with getting around. And 1,274 people started to use mobility aids. Compared with men, women were 49% more likely to transition from not needing mobility aids to needing to use them, according to the study which has been published in The Lancet Public Health. But were 21% less likely to go on to use mobility aids when they needed them. The authors said their study showed “barriers to access” for women. For both men and women, with every year that passed during the study period the need for mobility aids increased. People who were older, less educated, less wealthy or reported being disabled were more likely to “transition from no need to unmet need, and from unmet need to use”, the authors said, with this indicating a “higher prevalence of mobility limitations and MAP need overall among these groups”. They added: “Finally, marital or partnership status was not associated with transitioning to unmet need; however, single people were more likely to transition from unmet need to use compared with married or partnered people.” Jamie Danemayer, first author of the study from UCL Computer Science and UCL’s Global Disability Innovation Hub, said: “Our analysis suggests that there is a clear gender gap in access to mobility aids. “Though our data didn’t ascertain the reason why participants weren’t using mobility aids, other research tells us that women are often more likely than men to face obstacles such as cost barriers as a result of well-documented income disparities between genders. “Many mobility aids are designed for men rather than women, which we think may be a factor. “Using mobility aids can also make a disability visible, which can impact the safety and stigma experienced by women, in particular. “There’s a critical need for further research to identify and break down the barriers preventing women from accessing mobility aids that would improve their quality of life.” Professor Cathy Holloway, also from UCL, added: “Not having access to mobility aids when a person needs one can have a big impact on their independence, well-being and quality of life. “Our analysis suggests that women, in particular, regardless of other factors such as education and employment status, are not getting the support that they need.” Professor Shereen Hussein, senior author of the study and lead of the social care group at the London School of Hygiene & Tropical Medicine, said: “The research provides compelling evidence of gender disparities in accessing assistive technology, suggesting that cost, design bias, and social stigma are likely to disproportionally affect women. “This underscores the need for inclusive, gender-sensitive approaches in the design, production and inclusivity of assistive technologies.”U.S. stocks climbed after market superstar Nvidia and another round of companies said they’re making even fatter profits than expected. The S & P 500 pulled 0.5% higher Thursday after flipping between modest gains and losses several times in the morning. The Dow Jones Industrial Average jumped 1.1%, and the Nasdaq composite edged up less than 0.1%. Banks, smaller companies and other areas of the stock market that tend to do best when the economy is strong helped lead the way, while bitcoin briefly broke above $99,000. Crude oil, meanwhile, continued to rise. Treasury yields edged higher in the bond market. On Thursday: The S & P 500 rose 31.60 points, or 0.5%, to 5,948.71. The Dow Jones Industrial Average rose 461.88 points, or 1.1%, to 43,870.35. The Nasdaq composite rose 6.28 points, or less than 0.1%, to 18,972.42. The Russell 2000 index of smaller companies rose 38.48 points, or 1.7%, to 2,364.02. For the week: The S & P 500 is up 78.09 points, or 1.3%. The Dow is up 425.36 points, or 1%. The Nasdaq is up 292.30 points, or 1.6%. The Russell 2000 is up 60.18 points, or 2.6%. For the year: The S & P 500 is up 1,178.88 points, or 24.7%. The Dow is up 6,180.81 points, or 16.4%. The Nasdaq is up 3,961.07 points, or 26.4%. The Russell 2000 is up 336.94 points, or 16.6%.Ireland blamed Northern Ireland Office for ‘damaging leaks’, records show
None
MELBOURNE, Australia and INDIANAPOLIS, Dec. 30, 2024 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX; Nasdaq: TLX, Telix, the Company) today announces that it has submitted its Biologics License Application (BLA) to the United States (U.S.) Food and Drug Administration (FDA) for TLX250-CDx (Zircaix® 1 , 89 Zr- girentuximab) kidney cancer imaging 2 . TLX250-CDx is an investigational PET 3 drug product for the non-invasive diagnosis and characterization of clear cell renal cell carcinoma (ccRCC), the most common and aggressive form of kidney cancer. If approved, TLX250-CDx will be the first and only targeted PET agent specifically for kidney cancer to be commercially available in the U.S., further building on Telix’s successful urology imaging franchise. The FDA is expected to advise the PDUFA 4 goal date following the 60-day administrative review of the application. Kevin Richardson, Chief Executive Officer, Precision Medicine at Telix, stated, “We are pleased to be progressing the BLA for TLX250-CDx, which has been granted Breakthrough designation, and may therefore be eligible for priority review. Telix continues to target a full U.S. commercial launch in 2025 addressing a major unmet medical need for patients with suspected ccRCC.” About TLX250-CDx TLX250-CDx (Zircaix® 1 ) is an investigational PET agent that is under development for the diagnosis and characterization of ccRCC. Telix’s pivotal Phase III ZIRCON trial (ClinicalTrials.gov ID: NCT03849118 ) evaluating TLX250-CDx in 300 patients, of whom 284 were evaluable, met all primary and secondary endpoints, including showing 86% sensitivity and 87% specificity and a 93% positive-predictive value for ccRCC across three independent radiology readers 5 . Telix believes this demonstrated the ability of TLX250-CDx to reliably detect the clear cell phenotype and provide an accurate, non-invasive method for diagnosing and characterizing ccRCC. Confidence intervals exceeded expectations amongst all three readers, showing evidence of high accuracy and consistency of interpretation. About Telix Pharmaceuticals Limited Telix is a biopharmaceutical company focused on the development and commercialization of diagnostic and therapeutic radiopharmaceuticals and associated medical technologies. Telix is headquartered in Melbourne, Australia, with international operations in the United States, Europe (Belgium and Switzerland), and Japan. Telix is developing a portfolio of clinical and commercial stage products that aims to address significant unmet medical needs in oncology and rare diseases. Telix is listed on the Australian Securities Exchange (ASX: TLX) and the Nasdaq Global Select Market (Nasdaq: TLX). Telix’s lead imaging product, gallium-68 ( 68 Ga) gozetotide injection (also known as 68 Ga PSMA-11 and marketed under the brand name Illuccix®), has been approved by the U.S. Food and Drug Administration (FDA) 6 , by the Australian Therapeutic Goods Administration (TGA) 7 , and by Health Canada 8 . No other Telix product has received a marketing authorization in any jurisdiction. Visit www.telixpharma.com for further information about Telix, including details of the latest share price, announcements made to the ASX, investor and analyst presentations, news releases, event details and other publications that may be of interest. You can also follow Telix on X and LinkedIn . Telix Investor Relations Ms. Kyahn Williamson Telix Pharmaceuticals Limited SVP Investor Relations and Corporate Communications Email: kyahn.williamson@telixpharma.com This announcement has been authorised for release by the Telix Pharmaceuticals Limited Disclosure Committee on behalf of the Board. Legal Notices You should read this announcement together with our risk factors, as disclosed in our most recently filed reports with the Australian Securities Exchange (ASX), U.S. Securities and Exchange Commission (SEC), including our registration statement on Form 20-F filed with the SEC, or on our website. The information contained in this announcement is not intended to be an offer for subscription, invitation or recommendation with respect to securities of Telix Pharmaceuticals Limited (Telix) in any jurisdiction, including the United States. The information and opinions contained in this announcement are subject to change without notification. To the maximum extent permitted by law, Telix disclaims any obligation or undertaking to update or revise any information or opinions contained in this announcement, including any forward-looking statements (as referred to below), whether as a result of new information, future developments, a change in expectations or assumptions, or otherwise. No representation or warranty, express or implied, is made in relation to the accuracy or completeness of the information contained or opinions expressed in the course of this announcement. This announcement may contain forward-looking statements, including within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, that relate to anticipated future events, financial performance, plans, strategies or business developments. Forward-looking statements can generally be identified by the use of words such as “may”, “expect”, “intend”, “plan”, “estimate”, “anticipate”, “believe”, “outlook”, “forecast” and “guidance”, or the negative of these words or other similar terms or expressions. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to differ materially from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. Forward-looking statements are based on Telix’s good-faith assumptions as to the financial, market, regulatory and other risks and considerations that exist and affect Telix’s business and operations in the future and there can be no assurance that any of the assumptions will prove to be correct. In the context of Telix’s business, forward-looking statements may include, but are not limited to, statements about: the initiation, timing, progress and results of Telix’s preclinical and clinical trials, and Telix’s research and development programs; Telix’s ability to advance product candidates into, enrol and successfully complete, clinical studies, including multi-national clinical trials; the timing or likelihood of regulatory filings and approvals for Telix’s product candidates, manufacturing activities and product marketing activities; Telix’s sales, marketing and distribution and manufacturing capabilities and strategies; the commercialisation of Telix’s product candidates, if or when they have been approved; Telix’s ability to obtain an adequate supply of raw materials at reasonable costs for its products and product candidates; estimates of Telix’s expenses, future revenues and capital requirements; Telix’s financial performance; developments relating to Telix’s competitors and industry; and the pricing and reimbursement of Telix’s product candidates, if and after they have been approved. Telix’s actual results, performance or achievements may be materially different from those which may be expressed or implied by such statements, and the differences may be adverse. Accordingly, you should not place undue reliance on these forward-looking statements. ©2024 Telix Pharmaceuticals Limited. The Telix Pharmaceuticals®, Illuccix® and Zircaix® 1 names and logos are trademarks of Telix Pharmaceuticals Limited and its affiliates – all rights reserved. 1 Brand name subject to final regulatory approval. 2 Telix ASX disclosure 31 July 2024. The FDA requested additional data demonstrating adequate sterility assurance during dispensing of TLX250-CDx in the radiopharmacy production environment. 3 Positron emission tomography. 4 Prescription Drug User Fee Act. 5 Shuch et al. Lancet Oncol. 2024. Telix ASX disclosures 7 November 2022. 6 Telix ASX disclosure 20 December 2021. 7 Telix ASX disclosure 2 November 2021. 8 Telix ASX disclosure 14 October 2022.Ireland's Political Crossroads: Coalition Talks Intensify Post-Election
Hail Flutie: BC celebrates 40th anniversary of Miracle in MiamiThe Toronto Blue Jays are trying to secure the cornerstone of their franchise this offseason, but it is reportedly not close to happening. Per ESPN's Alden Gonzalez , the Blue Jays and Vladimir Guerrero Jr. have been in talks about an extension, but "are not considered to be close on one." Gonzalez noted that the hesitancy from Guerrero could affect Toronto's ability to bring in free agents and reported that a trade could be coming if the two sides can't reach a deal. This article will be updated soon to provide more information and analysis. For more from Bleacher Report on this topic and from around the sports world, check out our B/R app , homepage and social feeds—including Twitter , Instagram , Facebook and TikTok .